Emendo Biotherapeutics’ next generation CRISPR gene editing technologies achieve breakthrough results with allele-specific approach for ELANE-related Severe Congenital Neutropenia as presented at ASGCT Annual Meeting
Emendo Biotherapeutics revealed pre-clinical data for the treatment of ELANE-related Severe Congenital Neutropenia using an…